Update on new insulins

Standard human insulin preparations such as regular soluble insulin and neutral protamine Hagedorn (NPH) insulin have shortcomings in terms of their pharmacokinetic and pharmacodynamic properties that limit their clinical efficacy. In the last decade, due to advances in genetic engineering, structur...

Full description

Saved in:
Bibliographic Details
Published inAnales de pediatría (Barcelona, Spain : 2003) Vol. 70; no. 1; pp. 65 - 71
Main Author Tapia Ceballos, L
Format Journal Article
LanguageSpanish
Published Spain 01.01.2009
Subjects
Child
Diabetes Mellitus, Type 1 - drug therapy
Humans
Insulin - analogs & derivatives
Insulin - therapeutic use
Online AccessGet full text

Cover

More Information
Summary:Standard human insulin preparations such as regular soluble insulin and neutral protamine Hagedorn (NPH) insulin have shortcomings in terms of their pharmacokinetic and pharmacodynamic properties that limit their clinical efficacy. In the last decade, due to advances in genetic engineering, structurally modified insulin molecules have been developed with the aim of changing their galenic properties to make regular soluble insulin faster and NPH insulin slower. Five insulin analog preparations have become commercially available: two long-acting analogs (insulin glargine and detemir) and three rapid or fast-acting analogs (insulin lispro, aspart and glulisine). This article highlights the specific properties of these new insulin analog preparations and focuses on their potential advantages and disadvantages when used in children with diabetes mellitus.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 23
ISSN:1695-4033
DOI:10.1016/j.anpedi.2008.08.007